Clinical Trials Logo

Metabolic Syndrome X clinical trials

View clinical trials related to Metabolic Syndrome X.

Filter by:

NCT ID: NCT01172886 Recruiting - Clinical trials for Metabolic Syndrome as Breast Cancer Risk Factor

Metabolic Syndrome as Modifiable Risk Factor for Breast Cancer

Start date: January 2008
Phase: N/A
Study type: Observational

Healthy women and women with breast cancer have been enrolled in our nested case-control study between 2008 and 2009 in order to evaluate the association between metabolic syndrome and breast cancer, analyzing anthropometric parameters blood pressure, assessing serum HDL-C, triglyceride, fasting plasma glucose, insulin, testosterone and uric acid levels and administering a questionnaire about physical activity, food intake, tobacco use, alcohol abuse, personal and familial history of disease. Our data support the hypothesis that metabolic syndrome may be an indicator of breast cancer risk in postmenopausal women. The change of the hormonal arrangement in postmenopausal, along with an increase in visceral adiposity, probably favour the hormone dependent cell proliferation, which drives tumorigenesis. Adjustments in lifestyle with physical activity intensification and healthy diet may represent modifiable factors on which sporadic breast cancer primary prevention may work on.

NCT ID: NCT01119404 Recruiting - Metabolic Syndrome Clinical Trials

Hämeenlinna Metabolic Syndrome Research Program: Surrogate Indicators for Atherosclerosis

HMS-02
Start date: June 2003
Phase: N/A
Study type: Observational

Mechanisms that link metabolic syndrome to atherosclerosis are incompletely understood. As a part of Hämeenlinna Metabolic Syndrome Research Program (HMS) surrogate indicators for atherosclerosis are studied in 120 men with metabolic syndrome, 120 men with coronary heart disease and 80 physically active controls and in different settings.

NCT ID: NCT01046500 Recruiting - Metabolic Syndrome Clinical Trials

Myo-inositol Versus Metformin Administration in Post-menopausal Women With Metabolic Syndrome

Start date: January 2013
Phase: Phase 2
Study type: Interventional

Myo-Inositol is classified as a member of the vitamin B complex. It is a constituent of living cells and is widespread in many food. It is involved in a number of biological processes, including insulin signal transduction, resulting in modulating insulin sensitivity. One hundred post-menopausal women from 50 to 60 years old, affected by metabolic syndrome (criteria are described in NIH ATP III) will be randomized into two groups: 50 treated with myo-inositol 2 g twice per day and fifty treated with metformin for six months. Metformin is the drug usually used in diabetic and pre-diabetic conditions, as metabolic syndrome. The investigators hypothesize that the administration of myo-inositol would improve the insulin-receptor activity in these women, reducing insulin resistance as well as metformin. OUTCOME MEASURE: HOMA-IR, blood pressure level, serum triglycerides and cholesterol, BMI and waist circumference

NCT ID: NCT00914251 Recruiting - Metabolic Syndrome Clinical Trials

Vascular Effects of Hesperidin in Metabolic Syndrome

Start date: November 2008
Phase: Phase 2
Study type: Interventional

It has been suggested that cardiovascular risk factors either independently or in cluster (metabolic syndrome) increase the risk of both type 2 diabetes (DM2) and cardiovascular diseases (CVD). Consumption of citrus fruits is linked to reduced cardiovascular morbidity and mortality. Hesperidin is a flavanone abundant in citrus fruit with putative vasodilator actions in vitro. While molecular mechanisms of vascular actions of hesperidin begin to be explored, no data on in vivo vascular effect of this flavanone has been ever acquired.

NCT ID: NCT00790946 Recruiting - Obesity Clinical Trials

Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)

KACT
Start date: June 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to consider the following points in patients with hypertension who complicated by metabolic syndrome for Valsartan basis treatment and an existing, standard treatment. - Blood pressure control - Changing of adiponectin and plasminogen activator inhibitor-1 - Influence metabolizing and cardiac function, etc.

NCT ID: NCT00743301 Recruiting - Metabolic Syndrome Clinical Trials

The Effect of Palm Olein, Olive Oil and Lard and on Risk Markers of Cardiovascular Disease

A305
Start date: August 2008
Phase: N/A
Study type: Interventional

The aim of this study is to compare the effects of a diet rich in palm olein, a fraction of palm oil, to a diet rich in olive oil and a diet rich in Danish lard on plasma total-, LDL and HDL cholesterol as well as triacylglycerol (TAG), fasting insulin and glucose, C reactive protein and plasminogen activator inhibitor 1 in healthy men. The investigators hypothesis is that palm olein and olive oil will have the same effect on plasma total cholesterol, LDL- and HDL concentration and maybe also on the secondary outcome parameters that are related to cardiovascular disease risk. This may be caused by the differences in the sn-positioning of palmitic acid in palm olein. This difference may cause the palmitic acid in palm olein to be more prone to soap formations and excretion than palmitic acid from other sources, e.g. lard. This study is a double blinded, randomized, controlled 3 x 3 week crossover intervention study, without washout periods. The participants receive the three test foods in random order, decided by draw of lots. Blood samples are drawn in duplicate (on two following days) before and after each dietary period.

NCT ID: NCT00717509 Recruiting - Schizophrenia Clinical Trials

Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia

Start date: October 2007
Phase: N/A
Study type: Observational

We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.

NCT ID: NCT00716300 Recruiting - Clinical trials for Metabolic Syndrome X

High Density Lipoprotein (HDL) Functionality in Metabolic Syndrome

Start date: July 2008
Phase: N/A
Study type: Observational

The aim of the study is to examine the kinetic, anti-oxidant, anti-inflammatory and cellular cholesterol efflux properties of high-density lipoprotein (HDL) in subjects with the metabolic syndrome (MetS) and lean individuals.

NCT ID: NCT00700245 Recruiting - Healthy Clinical Trials

The Effect of Acute and Chronic Exercise at the Metabolic Syndrome and Markers of Inflammation in Obese Subjects

Start date: September 2006
Phase: N/A
Study type: Interventional

The human adipose and muscle -tissue produce and release a number of bioactive proteins which contributes to the chronic low grade of inflammatory status which is associated with obesity and plays an important role in the pathogenesis of type 2 diabetes and cardiovascular diseases. Study 1: Our aim is to investigate if exercise has independent and additive effects in combination with diet-induced weight loss on circulating levels of inflammatory markers and mRNA levels in subcutaneous adipose tissue (SAT) and skeletal muscle tissue (SM. Study 2: Our aim is to investigate whether gender and weight status plays a role in the metabolic response during two hours of acute exercise

NCT ID: NCT00696748 Recruiting - Metabolic Syndrome Clinical Trials

The Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men

NePlaM3
Start date: October 2005
Phase: Phase 3
Study type: Interventional

The objective of the study is to assess the effect of the testosterone therapy on the body composition, lipid and glucose metabolism, inflammatory markers in patients with metabolic syndrome and hypogonadism.